Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCRI AML16 trial in older patients with AML or high-risk MDS
ISRCTN11036523Phase 3Completed
- Sponsor
- Cardiff University
- Start
- Oct 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of daunorubicin, cytarabine, etoposide, tretinoin, azacitidine and 4 more in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (9 arms), sponsored by Cardiff University. Primary endpoints: Overall survival, Complete remission achievement and 4 more. Started Oct 2005; status: completed.
02
Drugs
daunorubicincytarabineetoposidetretinoinazacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN11036523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11036523.